Measuring beta-galactose exposure on platelets: Standardization and healthy reference values.
N‐acetylneuraminic acid
blood platelets
galactose
platelet count
references values
Journal
Research and practice in thrombosis and haemostasis
ISSN: 2475-0379
Titre abrégé: Res Pract Thromb Haemost
Pays: United States
ID NLM: 101703775
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
19
03
2020
revised:
28
04
2020
accepted:
30
04
2020
entrez:
2
11
2020
pubmed:
3
11
2020
medline:
3
11
2020
Statut:
epublish
Résumé
Correct diagnosis of the cause of thrombocytopenia is crucial for the appropriate management of patients. Hyposialylation/desialylation (characterized by abnormally high β-galactose exposure) accelerates platelet clearance and can lead to thrombocytopenia. However, the reference range for β-galactose exposure in healthy individuals has not been defined previously. The objective of the present study was to develop a standardized assay of platelet β-galactose exposure for implementation in a clinical laboratory. β-Galactose exposure was measured in platelet-rich plasma by using flow cytometry and We determined an optimal RCA concentration of 12.5 μg/mL. The measure was stable for up to 4 hours (mean fluorescence intensity [MFI]-RCA: 1233 ± 329 at 0 hour and 1480 ± 410 at 4 hours). The platelet count did not induce a variation of RCA and the measure of RCA was stable when tested up to 24 hours after blood collection (MFI-RCA: 1252 ± 434 at day 0 and 1140 ± 297 24 hours after blood sampling). To take into account the platelet size, results should be expressed as RCA/forward scatter ratio. We used the assay to study variability in 120 healthy adults, and we found that the ratio is independent of sex and blood group. We defined a normal range in a healthy population and several preanalytical and analytical variables were evaluated, together with positive and negative controls. This assay may assist in the diagnosis of thrombocytopenic diseases linked to changes in β-galactose exposure.
Sections du résumé
BACKGROUND
BACKGROUND
Correct diagnosis of the cause of thrombocytopenia is crucial for the appropriate management of patients. Hyposialylation/desialylation (characterized by abnormally high β-galactose exposure) accelerates platelet clearance and can lead to thrombocytopenia. However, the reference range for β-galactose exposure in healthy individuals has not been defined previously.
OBJECTIVE
OBJECTIVE
The objective of the present study was to develop a standardized assay of platelet β-galactose exposure for implementation in a clinical laboratory.
METHODS
METHODS
β-Galactose exposure was measured in platelet-rich plasma by using flow cytometry and
RESULTS
RESULTS
We determined an optimal RCA concentration of 12.5 μg/mL. The measure was stable for up to 4 hours (mean fluorescence intensity [MFI]-RCA: 1233 ± 329 at 0 hour and 1480 ± 410 at 4 hours). The platelet count did not induce a variation of RCA and the measure of RCA was stable when tested up to 24 hours after blood collection (MFI-RCA: 1252 ± 434 at day 0 and 1140 ± 297 24 hours after blood sampling). To take into account the platelet size, results should be expressed as RCA/forward scatter ratio. We used the assay to study variability in 120 healthy adults, and we found that the ratio is independent of sex and blood group.
CONCLUSION
CONCLUSIONS
We defined a normal range in a healthy population and several preanalytical and analytical variables were evaluated, together with positive and negative controls. This assay may assist in the diagnosis of thrombocytopenic diseases linked to changes in β-galactose exposure.
Identifiants
pubmed: 33134771
doi: 10.1002/rth2.12369
pii: S2475-0379(22)02039-8
pmc: PMC7586713
doi:
Types de publication
Journal Article
Langues
eng
Pagination
813-822Informations de copyright
© 2020 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis.
Références
J Hematol Oncol. 2017 May 11;10(1):104
pubmed: 28494777
Circ Heart Fail. 2016 Aug;9(8):
pubmed: 27507111
Blood. 2001 Feb 1;97(3):826-8
pubmed: 11157507
Eur J Haematol. 2000 Mar;64(3):151-6
pubmed: 10997880
Nat Commun. 2020 Jan 17;11(1):356
pubmed: 31953383
J Hematol Oncol. 2015 Oct 23;8:116
pubmed: 26497387
Haematologica. 2019 Dec;104(12):2493-2500
pubmed: 30819911
Ann Biol Clin (Paris). 2014 Sep-Oct;72(5):561-81
pubmed: 25336130
Neurology. 2013 Aug 13;81(7):681-7
pubmed: 23873973
Nat Commun. 2016 Sep 27;7:12863
pubmed: 27670775
J Exp Med. 2020 Apr 6;217(4):
pubmed: 31978220
Blood. 2018 Oct 25;132(17):1855-1858
pubmed: 29941673
Cell. 2003 Jan 10;112(1):87-97
pubmed: 12526796
Nucleic Acids Res. 2019 Jan 8;47(D1):D874-D880
pubmed: 30215764
Blood. 2009 Aug 20;114(8):1645-54
pubmed: 19520807
Eur Heart J. 2014 Oct 7;35(38):2663-71
pubmed: 24598983
Platelets. 2011;22(4):243-51
pubmed: 21329420
BMC Bioinformatics. 2006 Mar 09;7:123
pubmed: 16526949
Neuromuscul Disord. 2014 Dec;24(12):1068-72
pubmed: 25257349
Proc Natl Acad Sci U S A. 2017 Aug 1;114(31):8360-8365
pubmed: 28716912
Nat Med. 2009 Nov;15(11):1273-80
pubmed: 19783995
Vox Sang. 1968;15(3):194-202
pubmed: 5693226
Nat Commun. 2015 Jul 17;6:7737
pubmed: 26185093
Platelets. 2019;30(6):743-751
pubmed: 30296193
Haematologica. 2018 Dec;103(12):e613-e617
pubmed: 30115659
J Thromb Haemost. 2020 Mar;18(3):714-721
pubmed: 31869497
Circulation. 2014 Apr 1;129(13):1415-27
pubmed: 24566199
Int J Cardiol. 2016 Oct 15;221:719-25
pubmed: 27424316
Thromb Haemost. 2003 Jul;90(1):116-23
pubmed: 12876634
Nat Med. 2015 Jan;21(1):47-54
pubmed: 25485912
Sci Rep. 2019 Feb 18;9(1):2208
pubmed: 30778108
Am J Med Genet A. 2017 Nov;173(11):2906-2911
pubmed: 28856833
Science. 2003 Sep 12;301(5639):1531-4
pubmed: 12970565
N Engl J Med. 2016 Jul 28;375(4):335-44
pubmed: 27464202
Platelets. 2015;26(5):495-7
pubmed: 25166956
J Thromb Haemost. 2011 Jul;9 Suppl 1:35-43
pubmed: 21781240
J Hematol Oncol. 2017 Feb 8;10(1):46
pubmed: 28179000
Microsc Res Tech. 2014 Oct;77(10):841-9
pubmed: 25060388
Haematologica. 2019 Dec 19;:
pubmed: 31857361
Haematologica. 2014 Apr;99(4):e61-3
pubmed: 24532041
Pathophysiol Haemost Thromb. 2010;37(2-4):55-8
pubmed: 21063076
Catheter Cardiovasc Interv. 2015 Jan 1;85(1):130-7
pubmed: 24677617
Blood. 2018 Oct 25;132(17):1851-1854
pubmed: 30171045